Senior Medical Director
CurrentEarly phase immunotherapy drug development. Focus on novel clinical development approaches, T reg targeting, understanding and overcoming immunotherapy resistance mechanisms and irAs, optimizing IO combination approaches. Also novel ADCs, see Luke J, Barlesi JITC 2021; Chang, Emberley Blood, 2024